Involvement of <scp>kallikrein‐PAR2</scp> ‐proinflammatory pathway in severe trastuzumab‐induced cardiotoxicity-Reference-Cited by-同舟云学术

Involvement of kallikrein‐PAR2 ‐proinflammatory pathway in severe trastuzumab‐induced cardiotoxicity

Published:2022-08-19 Issue:10 Volume:113 Page:3449-3462
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Sasaki Ritsuko¹^ORCID,Kurebayashi Nagomi²^ORCID,Eguchi Hidetaka³^ORCID,Horimoto Yoshiya¹^ORCID,Shiga Takahiro⁴,Miyazaki Sakiko⁵,Kashiyama Taku²,Akamatsu Wado⁴,Saito Mitsue¹^ORCID

Affiliation:

1. Department of Breast Oncology Juntendo University Graduate School of Medicine Tokyo Japan

2. Department of Cellular and Molecular Pharmacology Juntendo University Graduate School of Medicine Tokyo Japan

3. Intractable Disease Research Center Juntendo University Graduate School of Medicine Tokyo Japan

4. Center for Genomic and Regenerative Medicine Juntendo University Graduate School of Medicine Tokyo Japan

5. Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan

Funder

Juntendo University

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15508

Reference53 articles.

1. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

2. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

3. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy

4. Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials

5. Trastuzumab cardiotoxicity: from clinical trials to experimental studies

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple metastases of human epidermal growth factor receptor 2‑positive, hormone receptor‑positive, pT1a pN0 breast cancer within 1 year after surgery: A case report;Oncology Letters;2024-06-12

2. Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer;Toxicological Research;2024-04-22

3. Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity;Cell Biology and Toxicology;2023-10-27

4. Blockade of Proteinase-Activated Receptor 2 (PAR2) Attenuates Neuroinflammation in Experimental Autoimmune Encephalomyelitis;Journal of Pharmacology and Experimental Therapeutics;2023-09-12

5. An integrative review of nonobvious puzzles of cellular and molecular cardiooncology;Cellular & Molecular Biology Letters;2023-05-23